Medios AG
Medios AG has a debt-to-equity ratio of 0.39 and a current ratio of 1.9, indicating a relatively balanced capital structure with moderate liquidity. However, the company's cash and equivalents are negative at -1,000 EUR, which raises concerns about its short-term liquidity position. The company's free cash flow of 44,934,000 EUR suggests it is generating positive cash from operations, but the negative net cash position indicates that the company may need to manage its working capital or debt obligations carefully. In terms of profitability, Medios AG has a return on equity of 2.99% and a return on assets of 1.7%, which are below the industry median for pharmaceutical companies. The company's operating income of 46,196,000 EUR and net income of 15,365,000 EUR indicate that it is profitable, but the low return metrics suggest that the company may not be utilizing its equity and assets as efficiently as its peers. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher risk if demand in its primary therapeutic areas declines or if regulatory changes impact its operations. Looking at the company's growth trajectory, the available data does not provide specific revenue growth projections for the current or next fiscal year. However, the company's operating cash flow of 52,273,000 EUR and free cash flow of 44,934,000 EUR suggest that it has the financial capacity to invest in research and development or expand its product portfolio. The risk assessment for Medios AG indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the need for the company to maintain sufficient liquidity to meet its obligations. The company's capital expenditure of -8,291,000 EUR suggests that it is not currently investing in new long-term assets, which could affect its long-term growth potential. Recent events related to Medios AG include analyst estimates for the company's stock price, with a mean price target of 23.00 EUR and a median price target of 24.00 EUR. The mean recommendation from analysts is 1.40, indicating a generally positive outlook, with three strong-buy ratings and two buy ratings.
Business. Medios AG is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the therapeutic areas of oncology and rare diseases.
Classification. Medios AG is classified in the Pharmaceuticals industry under the Healthcare economic sector with a confidence level of 0.92.
- Medios AG has a balanced capital structure with a debt-to-equity ratio of 0.39 and a current ratio of 1.9.
- The company's return on equity and return on assets are below the industry median, indicating lower efficiency in utilizing equity and assets.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Analysts have a generally positive outlook on Medios AG, with a mean price target of 23.00 EUR and a mean recommendation of 1.40.
- The company has a medium liquidity risk and a low dilution risk, but its negative net cash position requires careful management.
- --
- # RATIONALES
- ```json
- Net cash is negative after subtracting total debt.